Extended Data Fig. 4: Progression-free and overall survival prognostication based on radiographic RECIST response for all patients on BR.36 with evaluable RECIST responses.
From: ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
RECIST response at 12 weeks less clearly distinguished patients with complete/partial responses compared to patients with stable disease for progression-free (8.31 vs 4.27 months, shown in panel a) and overall survival (not reached vs 16.89 months, shown in panel b).
